Q4 2026 IPCA Laboratories Ltd Earnings Call Transcript

Jun 01, 2026 / 10:00AM GMT

Release Date Price: ₹1490.4 (-2.23%)

Transcript

Key Points

Positve

Ipca Laboratories Ltd (BOM:524494) reported a 12% growth in its domestic formulation business for Q4 FY26, reaching INR853 crore compared to INR764 crore in Q4 FY25.
The company's export formulation business grew by 9% in FY26, reaching INR2,083 crore from INR1,919 crore in the previous year.
Standalone EBITDA margin improved significantly to 25.27% in Q4 FY26 from 21.19% in Q4 FY25, marking an improvement of 4.08%.
The company achieved a consolidated revenue growth of 8% for the year, reaching INR9,646 crore compared to INR8,940 crore in FY25.
Ipca Laboratories Ltd (BOM:524494) maintained a strong market position with six of its brands featuring among the top 300 in the industry.

Negative

The institutional business saw a decline, with revenue dropping to INR270 crore from INR355 crore in the previous financial year.
Unichem's EBITDA margins declined from 12% to 8%, impacting the overall consolidated margins.
Supply chain disruptions and increased raw material costs, particularly in packaging and solvents, are expected to impact margins in FY27.
The company faces challenges in the institutional segment due to funding constraints, leading to a 33% decline in revenue.
Lyka Labs, an associate company, is experiencing deteriorating performance, raising concerns about potential impairments similar to those taken for Krebs Bio.

Operator

Ladies and gentlemen, good day, and welcome to the Ipca Labs earnings call Q4 FY26, hosted by DAM Capital Advisors Limited. (Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Mr. Nitin Agarwal from DAM Capital Advisors Limited. Thank you, and over to you, sir.

Nitin Agarwal

DAM Capital Advisors Ltd - Analyst

Thank you. Hi, good afternoon, everyone, and a very warm welcome to Ipca Labs Limited's Q4 FY26 post-results earnings call hosted by DAM Capital Advisors Limited.

On the call today, we have representing Ipca Lab management, Mr. AK Jain, Managing Director, and Mr. Harish Kamath, Corporate Counsel and Company Secretary. I will hand over the call to Mr. Jain to make the opening comments, and he will open the floor for questions. Please go ahead, sir.

Ajit Kumar Jain

IPCA Laboratories Ltd - Managing Director & CFO

Thanks, Nitin. DAM Capital for organizing this call. Today's hearing call and discussions answer given may include some

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.